Overview

Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential drug-drug interactions between ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell non-Hodgkin's lymphoma (NHL).
Phase:
Phase 1
Details
Lead Sponsor:
Novartis
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Bendamustine Hydrochloride
Ofatumumab